Rhenman & Partners Asset Management AB
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), Rhenman & Partners Asset Management AB reported 84 stock positions worth $1.1 billion. Its top holding was Cigna (CI) at 4.7% of the portfolio, followed by Eli Lilly (LLY, 4.0%) and Tenet Healthcare (THC, 3.8%). Compared with Q4 2023, it opened 10 new positions, sold out of 11, added to 31 and reduced 41. The biggest buy was Cigna (CI, shares +192%) and the biggest sale Medtronic (MDT, shares −45%).
- Most Recent 13F
- Q2 2026
- Location
- Stockholm, V7
- CIK
- 0001599882
- Portfolio Value
- $1.1B (Q1 2024)
- SEC Filing
- 0001213900-24-042547 ↗ filed May 14, 2024
Holdings Value
Holdings 84 stocks · $1.1B
| CI The Cigna Group | 4.72% | 137,171 | $49.8M | Add +191.8% |
| LLY Eli Lilly & Co. | 3.99% | 54,175 | $42.1M | Reduce -30.6% |
| THC Tenet Healthcare Corp. | 3.79% | 380,000 | $39.9M | Add +8.1% |
| BSX Boston Scientific Corp. | 3.78% | 582,000 | $39.9M | Reduce -22.4% |
| ELV Elevance Health Inc. | 3.42% | 69,500 | $36.0M | Add +434.6% |
| ABBV Abbvie Inc. | 3.27% | 189,500 | $34.5M | Add +13.5% |
| HCA HCA Healthcare Inc. | 3.16% | 100,000 | $33.4M | Reduce -8.3% |
| REGN Regeneron Pharmaceuticals | 3.13% | 34,300 | $33.0M | Reduce -12.1% |
| COO The Cooper Cos Inc. | 2.89% | 301,000 | $30.5M | Add +28.6% |
| MRK Merck & Co. Inc. | 2.73% | 218,500 | $28.8M | Add +48.1% |
| BDX Becton Dickinson and Co. | 2.72% | 116,000 | $28.7M | New |
| MDT Medtronic PLC | 2.68% | 325,000 | $28.3M | Reduce -45.0% |
| OSCR Oscar Health Inc. Class A | 2.38% | 1,691,522 | $25.2M | Add +41.9% |
| PRCT Procept Biorobotics Corp. | 2.28% | 487,063 | $24.1M | Add +57.1% |
| MCK McKesson Corp. | 2.24% | 44,000 | $23.6M | Reduce -4.3% |
| VRTX Vertex Pharmaceuticals Inc. | 2.24% | 56,500 | $23.6M | Reduce -40.5% |
| NTRA Natera Inc. | 2.08% | 240,000 | $22.0M | Reduce -2.0% |
| ABT Abbott Laboratories | 1.99% | 185,000 | $21.0M | Reduce -9.8% |
| SWAV Shockwave Medical Inc. | 1.98% | 64,000 | $20.8M | Reduce -54.3% |
| BMRN Biomarin Pharmaceutical Inc. | 1.97% | 237,500 | $20.7M | Reduce -15.9% |
| ISRG Intuitive Surgical Inc. | 1.91% | 50,500 | $20.2M | Reduce -20.5% |
| UNH Unitedhealth Group Inc. | 1.90% | 40,500 | $20.0M | Reduce -25.0% |
| DXCM Dexcom Inc. | 1.82% | 138,500 | $19.2M | Add +25.9% |
| JAZZ Jazz Pharmaceuticals PLC | 1.67% | 146,729 | $17.7M | Add +18.7% |
| RPRX Royalty Pharma PLC Class A | 1.57% | 544,697 | $16.5M | Add +26.8% |
| ALGN Align Technology Inc. | 1.55% | 50,000 | $16.4M | Add +85.2% |
| DVAX Dynavax Technologies Corp. | 1.36% | 1,157,361 | $14.4M | Add +44.7% |
| IOVA Iovance Biotherapeutics Inc. | 1.34% | 955,000 | $14.2M | Reduce -14.5% |
| CYTK Cytokinetics Inc. | 1.31% | 197,515 | $13.8M | Add +31.8% |
| BIIB Biogen Inc. | 1.16% | 56,800 | $12.2M | Reduce -3.2% |
| VKTX Viking Therapeutics Inc. | 1.13% | 145,000 | $11.9M | Reduce -19.4% |
| AXSM Axsome Therapeutics Inc. | 1.09% | 143,600 | $11.5M | Add +81.5% |
| APLS Apellis Pharmaceuticals Inc. | 0.99% | 178,395 | $10.5M | Add +77.7% |
| COR Cencora Inc. | 0.98% | 42,500 | $10.3M | Reduce -55.7% |
| PEN Penumbra Inc. | 0.97% | 46,000 | $10.3M | Add +1740.0% |
| CNC Centene Corp. | 0.96% | 129,000 | $10.1M | Reduce -4.4% |
| ALHC Alignment Healthcare Inc. | 0.95% | 2,022,736 | $10.0M | Add +112.9% |
| EXAS Exact Sciences Corp. | 0.94% | 143,000 | $9.9M | Reduce -13.3% |
| MDGL Madrigal Pharmaceuticals Inc. | 0.92% | 36,500 | $9.7M | Add +62.2% |
| ITCI Intra-Cellular Therapies Inc. | 0.90% | 137,500 | $9.5M | Add +52.8% |
| GILD Gilead Sciences Inc. | 0.88% | 127,000 | $9.3M | Reduce -51.0% |
| INSP Inspire Medical Systems Inc. | 0.85% | 42,000 | $9.0M | Add +133.3% |
| ZBH Zimmer Biomet Holdings Inc. | 0.84% | 67,500 | $8.9M | Add +22.7% |
| NBIX Neurocrine Biosciences Inc. | 0.77% | 59,000 | $8.1M | Reduce -4.8% |
| IQV Iqvia Holdings Inc. | 0.74% | 31,000 | $7.8M | Reduce -31.1% |
| NVCR Novocure Ltd. | 0.73% | 495,307 | $7.7M | Add +209.6% |
| EPIX Essa Pharma Inc. | 0.73% | 911,820 | $7.7M | Add +155.8% |
| TMO Thermo Fisher Scientific Inc. | 0.72% | 13,000 | $7.6M | Reduce -61.2% |
| ARVN Arvinas Inc. | 0.67% | 170,000 | $7.0M | Add +26.6% |
| NUVL Nuvalent Inc. Class A | 0.62% | 87,500 | $6.6M | Reduce -22.5% |
| ALNY Alnylam Pharmaceuticals Inc. | 0.60% | 42,300 | $6.3M | Add +12.8% |
| PODD Insulet Corp. | 0.56% | 34,750 | $6.0M | Add +82.9% |
| IMCR Immunocore Holdings PLC-ADR | 0.49% | 79,778 | $5.2M | Reduce -5.3% |
| XNCR Xencor Inc. | 0.46% | 218,750 | $4.8M | Reduce -2.8% |
| AVTR Avantor Inc. | 0.41% | 171,000 | $4.4M | Reduce -41.4% |
| SNDX Syndax Pharmaceuticals Inc. | 0.40% | 178,500 | $4.2M | New |
| IMVT Immunovant Inc. | 0.38% | 125,500 | $4.1M | Reduce -14.1% |
| JANX Janux Therapeutics Inc. | 0.37% | 104,500 | $3.9M | New |
| KURA Kura Oncology Inc. | 0.34% | 166,526 | $3.6M | New |
| RVNC Revance Therapeutics Inc. | 0.33% | 701,707 | $3.5M | Add +47.5% |
| CRL Charles River Laboratories | 0.33% | 12,700 | $3.4M | Reduce -66.6% |
| ALPN Alpine Immune Sciences Inc. | 0.32% | 85,500 | $3.4M | New |
| KRYS Krystal Biotech Inc. | 0.32% | 19,000 | $3.4M | New |
| AUGX Augmedix Inc. | 0.31% | 800,000 | $3.3M | New |
| BBIO Bridgebio Pharma Inc. | 0.31% | 104,500 | $3.2M | Reduce -22.6% |
| ALKS Alkermes PLC | 0.28% | 110,000 | $3.0M | Reduce -67.7% |
| SYK Stryker Corp. | 0.27% | 8,000 | $2.9M | Add +60.0% |
| DHR Danaher Corp. | 0.26% | 11,000 | $2.7M | Reduce -85.9% |
| NARI Inari Medical Inc. | 0.26% | 56,420 | $2.7M | New |
| GKOS Glaukos Corp. | 0.24% | 27,000 | $2.5M | Reduce -77.5% |
| EHC Encompass Health Corp. | 0.23% | 29,000 | $2.4M | New |
| MIRM Mirum Pharmaceuticals Inc. | 0.22% | 92,250 | $2.3M | New |
| PRVA Privia Health Group Inc. | 0.21% | 114,000 | $2.2M | Reduce -75.2% |
| PLRX Pliant Therapeutics Inc. | 0.21% | 145,250 | $2.2M | Add +28.8% |
| INMB Inmune Bio Inc. | 0.20% | 178,284 | $2.1M | No change |
| RLAY Relay Therapeutics Inc. | 0.18% | 230,000 | $1.9M | Reduce -41.0% |
| IGMS Igm Biosciences Inc. | 0.18% | 195,000 | $1.9M | Reduce -2.5% |
| BRKR Bruker Corp. | 0.18% | 20,000 | $1.9M | Add +25.0% |
| TGTX TG Therapeutics Inc. | 0.18% | 123,500 | $1.9M | Reduce -22.8% |
| NTLA Intellia Therapeutics Inc. | 0.13% | 48,000 | $1.3M | Reduce -4.0% |
| AMGN Amgen Inc. | 0.11% | 4,250 | $1.2M | Reduce -5.6% |
| TECH Bio-Techne Corp. | 0.11% | 16,000 | $1.1M | No change |
| ACHC Acadia Healthcare Co. Inc. | 0.09% | 12,624 | $1.0M | Reduce -32.2% |
| RGEN Repligen Corp. | 0.09% | 5,000 | $920K | Reduce -50.0% |
Portfolio Sells Q4 2023 → Q1 2024
| MDT Medtronic PLC | Reduce -45.0% | 2.68% | −2.18 |
| HUM Humana Inc. | Sold out | 0.00% | −1.79 |
| PFE Pfizer Inc. | Sold out | 0.00% | −1.67 |
| VRTX Vertex Pharmaceuticals Inc. | Reduce -40.5% | 2.24% | −1.62 |
| DHR Danaher Corp. | Reduce -85.9% | 0.26% | −1.54 |
| AXONICS INC | Sold out | 0.00% | −1.37 |
| GILD Gilead Sciences Inc. | Reduce -51.0% | 0.88% | −1.21 |
| CVS CVS Health Corp. | Sold out | 0.00% | −1.08 |
| TMO Thermo Fisher Scientific Inc. | Reduce -61.2% | 0.72% | −1.06 |
| COR Cencora Inc. | Reduce -55.7% | 0.98% | −0.99 |
| UNH Unitedhealth Group Inc. | Reduce -25.0% | 1.90% | −0.94 |
| PRVA Privia Health Group Inc. | Reduce -75.2% | 0.21% | −0.85 |
| EVH Evolent Health Inc. Class A | Sold out | 0.00% | −0.76 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -15.9% | 1.97% | −0.76 |
| GKOS Glaukos Corp. | Reduce -77.5% | 0.24% | −0.71 |
| SWAV Shockwave Medical Inc. | Reduce -54.3% | 1.98% | −0.69 |
| ALKS Alkermes PLC | Reduce -67.7% | 0.28% | −0.66 |
| CRL Charles River Laboratories | Reduce -66.6% | 0.33% | −0.57 |
| BSX Boston Scientific Corp. | Reduce -22.4% | 3.78% | −0.55 |
| LLY Eli Lilly & Co. | Reduce -30.6% | 3.99% | −0.55 |
| BIIB Biogen Inc. | Reduce -3.2% | 1.16% | −0.36 |
| LH Laboratory CRP of Amer Hldgs | Sold out | 0.00% | −0.34 |
| WST West Pharmaceutical Services | Sold out | 0.00% | −0.32 |
| IQV Iqvia Holdings Inc. | Reduce -31.1% | 0.74% | −0.30 |
| REGN Regeneron Pharmaceuticals | Reduce -12.1% | 3.13% | −0.29 |
| EXAS Exact Sciences Corp. | Reduce -13.3% | 0.94% | −0.28 |
| HCAT Health Catalyst Inc. | Sold out | 0.00% | −0.28 |
| ABT Abbott Laboratories | Reduce -9.8% | 1.99% | −0.26 |
| AVTR Avantor Inc. | Reduce -41.4% | 0.41% | −0.25 |
| RLAY Relay Therapeutics Inc. | Reduce -41.0% | 0.18% | −0.25 |
| LNTH Lantheus Holdings Inc. | Sold out | 0.00% | −0.25 |
| BBIO Bridgebio Pharma Inc. | Reduce -22.6% | 0.31% | −0.24 |
| IMVT Immunovant Inc. | Reduce -14.1% | 0.38% | −0.23 |
| ISRG Intuitive Surgical Inc. | Reduce -20.5% | 1.91% | −0.23 |
| NUVL Nuvalent Inc. Class A | Reduce -22.5% | 0.62% | −0.21 |
| TGTX TG Therapeutics Inc. | Reduce -22.8% | 0.18% | −0.10 |
| RGEN Repligen Corp. | Reduce -50.0% | 0.09% | −0.09 |
| IMCR Immunocore Holdings PLC-ADR | Reduce -5.3% | 0.49% | −0.08 |
| ACHC Acadia Healthcare Co. Inc. | Reduce -32.2% | 0.09% | −0.05 |
| NBIX Neurocrine Biosciences Inc. | Reduce -4.8% | 0.77% | −0.04 |
| CNC Centene Corp. | Reduce -4.4% | 0.96% | −0.04 |
| LUNG Pulmonx Corp. | Sold out | 0.00% | −0.03 |
| NTLA Intellia Therapeutics Inc. | Reduce -4.0% | 0.13% | −0.03 |
| MGTX Meiragtx Holdings PLC | Sold out | 0.00% | −0.02 |
| XNCR Xencor Inc. | Reduce -2.8% | 0.46% | −0.02 |
| AMGN Amgen Inc. | Reduce -5.6% | 0.11% | −0.01 |
| IGMS Igm Biosciences Inc. | Reduce -2.5% | 0.18% | +0.01 |
| MCK McKesson Corp. | Reduce -4.3% | 2.24% | +0.11 |
| HCA HCA Healthcare Inc. | Reduce -8.3% | 3.16% | +0.21 |
| IOVA Iovance Biotherapeutics Inc. | Reduce -14.5% | 1.34% | +0.43 |
Portfolio Buys Q4 2023 → Q1 2024
| CI The Cigna Group | Add +191.8% | 4.72% | +3.32 |
| ELV Elevance Health Inc. | Add +434.6% | 3.42% | +2.80 |
| BDX Becton Dickinson and Co. | New | 2.72% | +2.72 |
| OSCR Oscar Health Inc. Class A | Add +41.9% | 2.38% | +1.29 |
| THC Tenet Healthcare Corp. | Add +8.1% | 3.79% | +1.13 |
| MRK Merck & Co. Inc. | Add +48.1% | 2.73% | +1.13 |
| PRCT Procept Biorobotics Corp. | Add +57.1% | 2.28% | +0.98 |
| PEN Penumbra Inc. | Add +1740.0% | 0.97% | +0.91 |
| ALGN Align Technology Inc. | Add +85.2% | 1.55% | +0.81 |
| ABBV Abbvie Inc. | Add +13.5% | 3.27% | +0.69 |
| COO The Cooper Cos Inc. | Add +28.6% | 2.89% | +0.68 |
| EPIX Essa Pharma Inc. | Add +155.8% | 0.73% | +0.50 |
| NVCR Novocure Ltd. | Add +209.6% | 0.73% | +0.50 |
| INSP Inspire Medical Systems Inc. | Add +133.3% | 0.85% | +0.49 |
| AXSM Axsome Therapeutics Inc. | Add +81.5% | 1.09% | +0.46 |
| DXCM Dexcom Inc. | Add +25.9% | 1.82% | +0.46 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +62.2% | 0.92% | +0.40 |
| SNDX Syndax Pharmaceuticals Inc. | New | 0.40% | +0.40 |
| APLS Apellis Pharmaceuticals Inc. | Add +77.7% | 0.99% | +0.39 |
| JANX Janux Therapeutics Inc. | New | 0.37% | +0.37 |
| RPRX Royalty Pharma PLC Class A | Add +26.8% | 1.57% | +0.36 |
| KURA Kura Oncology Inc. | New | 0.34% | +0.34 |
| ALPN Alpine Immune Sciences Inc. | New | 0.32% | +0.32 |
| KRYS Krystal Biotech Inc. | New | 0.32% | +0.32 |
| AUGX Augmedix Inc. | New | 0.31% | +0.31 |
| ITCI Intra-Cellular Therapies Inc. | Add +52.8% | 0.90% | +0.26 |
| NARI Inari Medical Inc. | New | 0.26% | +0.26 |
| DVAX Dynavax Technologies Corp. | Add +44.7% | 1.36% | +0.24 |
| EHC Encompass Health Corp. | New | 0.23% | +0.23 |
| MIRM Mirum Pharmaceuticals Inc. | New | 0.22% | +0.22 |
| ZBH Zimmer Biomet Holdings Inc. | Add +22.7% | 0.84% | +0.18 |
| JAZZ Jazz Pharmaceuticals PLC | Add +18.7% | 1.67% | +0.16 |
| PODD Insulet Corp. | Add +82.9% | 0.56% | +0.15 |
| ALHC Alignment Healthcare Inc. | Add +112.9% | 0.95% | +0.13 |
| SYK Stryker Corp. | Add +60.0% | 0.27% | +0.12 |
| ARVN Arvinas Inc. | Add +26.6% | 0.67% | +0.11 |
| CYTK Cytokinetics Inc. | Add +31.8% | 1.31% | +0.06 |
| BRKR Bruker Corp. | Add +25.0% | 0.18% | +0.06 |
| PLRX Pliant Therapeutics Inc. | Add +28.8% | 0.21% | +0.00 |
| RVNC Revance Therapeutics Inc. | Add +47.5% | 0.33% | −0.09 |
| ALNY Alnylam Pharmaceuticals Inc. | Add +12.8% | 0.60% | −0.12 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $1.1B | UNH, CVS, AZN, MRK, LLY |
| Q1 2026 | 86 | $810.5M | BSX, REGN, LLY, INSM, CVS |
| Q4 2025 | 94 | $1.1B | REGN, LLY, BSX, MDT, ISRG |
| Q3 2025 | 92 | $903.7M | BSX, LLY, ABBV, DHR, ALHC |
| Q2 2025 | 90 | $791.0M | LLY, BSX, VRTX, GKOS, ISRG |
| Q1 2025 | 94 | $870.0M | UNH, LLY, VRTX, MCK, BSX |
| Q4 2024 | 92 | $972.9M | BSX, LLY, PRCT, ISRG, REGN |
| Q3 2024 | 95 | $1.2B | BSX, UNH, LLY, REGN, THC |
| Q2 2024 | 93 | $1.0B | UNH, ELV, BSX, LLY, REGN |
| Q1 2024 | 84 | $1.1B | CI, LLY, THC, BSX, ELV |